Salud y Farmacia — GLP-1 Superciclo 2026
industrias
Empresas documentadas: Novo Nordisk, Eli Lilly, Amgen, AstraZeneca, Boehringer Ingelheim, Merck, Pfizer, Sanofi.
Sub-página dedicada al GLP-1 superciclo dentro de la industria salud/farma. Actualización mayor post CIO operación investigación masiva 82 targets.
---
GLP-1 Superciclo: $168B 2035 — CAGR 22.4%
| Métrica (Emergen Research 2026) | Valor | Significado | |----------------------------------|-------|-------------| | Market size 2025 | $26.8B | Base real | | Market size 2035 | $168B | Proyección estructural | | Revenue CAGR 2025-35 | 22.4% | Superciclo confirmado | | Eligible population | 890M obese adults | Global, no solo US/EU | | Ecosystem value 2025-35 | $1.2T cumulative | Healthcare system impact | | US users 2025 | ~10M | 6M 2024, 5M 2023 | | US users 2030 | 25-30M | JPMorgan forecast | | Global users 2030 | ~100M | Extrapolación |
Fase actual: Emergencia (2025-2026) → Diferenciación (2027-2028) → Madurez (2029-2030)
---
Duopolio actual: Lilly vs Novo 2026
| Empresa | Portfolio | Revenue 2025 | Growth | Posición | |---------|-----------|--------------|--------|----------| | Eli Lilly | Mounjaro (diabetes), Zepbound (obesidad) | $19.3B Q4 2025 | +43% YoY | Líder aceleración | | | Foundayo (oral orforglipron) | FDA approved Apr 2026 | Triple agonista pipeline | | | Retatrutide (triple agonist) | Phase 3 | 2030+ | | Novo Nordisk | Ozempic (diabetes), Wegovy (obesidad) | DKK 201.8B ($29.3B) 2024 | +26% CER 2024 | Líder estable | | | Rybelsus (oral semaglutide) | DKK 65.1B ($9.5B) 2024 | +57% CER | Oral advantage | | | CagriSema (semaglutide+cagrilintide) | Phase 3 | 2027+ |
Desacoplamiento 2025: Lilly tirzepatide Q4 2025 $11.6B vs Novo Ozempic DKK 31.8B (+1% CER) → Lilly lidera crecimiento.
---
Catalizadores estructurales 2026-2030
1. Oral GLP-1s: Game changer — manufacturabilidad vs inyectables
| Producto | Tipo | Estado | Impacto | |----------|------|--------|---------| | Foundayo (Lilly) | Oral small molecule | FDA approved Apr 2026 | No fill-finish constraint | | | Orforglipron | 27.3 lb weight loss (Phase 3) | Daily dosing, no food/water | | Wegovy oral (Novo) | Oral semaglutide | FDA approved Dec 2025 | 16.6% weight loss at 64 weeks | | | Rybelsus oral | Existing | Daily, but requires fasting | | Amycretin (Novo) | GLP-1/amylin oral | Phase 1 | 13% weight loss in 12 weeks |
Manufacturabilidad: Oral = tablet lines vs injectables = cold chain, sterile fill-finish → escala masiva.
2. Manufacturing capacity: $50B+ capex — API bottleneck
| Empresa | Investment | Timeline | Focus | |---------|-----------|----------|-------| | Eli Lilly | $27B (2025) | 2027-2030 | API + injectables + oral | | | Lebanon, IN | 2027 | Largest API site US history | | | Goochland, VA | 2028 | Integrated API + drug-product | | | Germany (Lonza) | 2028 | GLP-1 API facility | | Novo Nordisk | $9B (2025) | 2027-2029 | Fill-finish + API | | | Clayton, NC #2 | 2027-2029 | 1.4M sq ft, 1,000 jobs | | | Athlone, Ireland | 2027-2028 | Oral GLP-1 capacity | | | Kalundborg, Denmark | 2024 | API expansion |
Bottleneck actual: Fill-finish capacity → 35% demand > supply through 2027 (Emergen Research).
3. Label expansions: Beyond obesidad → comorbidades
| Indicación | Empresa | Estado | Impacto | |------------|---------|--------|---------| | HFpEF (heart failure) | Novo semaglutide | FDA review Q1 2026 | 3.5M US patients | | Sleep apnea | Lilly tirzepatide | Phase 3 | Sleep quality improvement | | NASH (liver disease) | Boehringer survodutide | Phase 3 | Metabolic steatohepatitis | | Kidney disease | Multiple | Phase 2-3 | Renal protection | | Neurodegenerative | Multiple | Preclinical | Alzheimer's, Parkinson's |
Impacto: Cada nueva indicación duplica el mercado addressable.
4. Payer coverage: IRA pricing access inflection
| Payer Type | Coverage Status | Pricing Impact | |------------|----------------|---------------| | Medicare Part D | Ozempic/Wegovy in Round 2 | $274/month vs $959 list (Jan 2027) | | | Tirzepatide not in Round 2 | Protected until 2029+ | | Commercial insurance | ~25% cover obesity | Near-universal for diabetes | | Medicaid | Limited coverage | Expansion ongoing | | Self-pay | $349-$1,349/month | Cash market growing |
Timeline crítico: Jan 2027 IRA pricing takes effect → access expansion.
---
Pipeline: Next wave 2026-2030
Triple agonists (2027-2030)
- Retatrutide (Lilly): Triple GLP-1/GIP/glucagon → Phase 3 obesidad
- CagriSema (Novo): Semaglutide + cagrilintide → Phase 3
- Survodutide (Boehringer): Glucagon + GLP-1 → NASH + obesidad
Oral formulations (2026-2027)
- Foundayo (Lilly): Approved Apr 2026 → oral small molecule
- Wegovy oral (Novo): Approved Dec 2025 → oral semaglutide
- Amycretin (Novo): GLP-1 + amylin → Phase 1
Combination therapies (2028-2030)
- Multiple GLP-1 combinations → enhanced efficacy, tolerability
- Fixed-dose combinations → adherence improvement
Biosimilar inflection (2031-2033)
- Semaglutide biosimilars: FDA guidance Mar 2025 → first by 2033
- Price compression: 70-80% below brand → access expansion
---
Impacto sistema: $1.2T ecosystem value
Healthcare system impact
| Sector | Impact | Timeline | |--------|--------|----------| | Cardiovascular procedures | Reduced events | 2027-2030 | | Diabetes management | Lower HbA1c, complications | 2026+ | | Kidney disease | Slowed progression | 2028+ | | Healthcare costs | $30-55B annual reduction | 2030-2034 |
Food & beverage impact (JPMorgan 2026)
- US households with GLP-1 users: -12% snack food, -9% sugary beverages, +7% protein
- Industry revenue reduction: $30-55B by 2030-2034
- Consumer behavior: 21% fewer calories, 31% less grocery spending
Food industry response
- Nestlé: Dedicated GLP-1 nutrition platform (Oct 2024)
- Conagra: 40 SKUs reformulated for reduced portions + protein
- General Mills: Protein-focused product development
---
Jugadores principales — Posicionamiento 2026
| Empresa | Modelo | Posición | Thesis Status | |---------|--------|----------|---------------| | Eli Lilly | GLP-1 platform (tirzepatide + orforglipron) | BUY | Triple agonist, oral advantage, IRA protection until 2029 | | Novo Nordisk | GLP-1 legacy (semaglutide + oral) | WATCHLIST | Strong brand but IRA exposure 2027, CagriSema execution risk | | Amgen | MariTide (once monthly dual action) | WATCHLIST | Long-acting formulation, obesity entry | | Boehringer Ingelheim | Survodutide (glucagon + GLP-1) | WATCHLIST | NASH + obesity, metabolic focus | | AstraZeneca | Partnership with CSPC China | WATCHLIST | China market access, innovation sourcing | | Merck | Keytruda (oncology crossover) | WATCHLIST | Cardio-metabolic potential | | Pfizer | Metsera acquisition (2025) | WATCHLIST | Obesity portfolio expansion | | Sanofi | Multiple GLP-1 partnerships | WATCHLIST | Late entry, potential upside |
---
KPIs para valorar empresa GLP-1 (actualizado)
- Portfolio diversification: Multiple GLP-1 assets across routes/oral/injectable
- Manufacturing capacity: API vs fill-finish, geographic diversification
- Payer coverage: Commercial/Medicaid/Medicare penetration, IRA exposure timing
- Pipeline depth: Next-gen agonists, oral formulations, combination therapies
- Real-world evidence: Persistence rates, cardiovascular outcomes, system cost savings
- Global reach: US/EU/Japan/China market access, emerging market penetration
- Biosimilar strategy: Patent cliff timing, biosimilar pipeline development
- Manufacturing economics: Cost per dose, scale advantages, cold chain requirements
---
Banderas rojas sector (actualizado)
- IRA pricing compression: Semaglutide exposed Jan 2027 → $274/month vs $959 list
- Manufacturing overcapacity: Fill-finish capacity at risk if oral wins share faster
- Persistence rates: Current 30-35% → needs to stabilize >40% for system value
- Competition intensification: Multiple entrants → pricing pressure, differentiation challenge
- Oral adoption: Adherence challenges with daily dosing vs weekly injections
- Global access: Pricing in emerging markets, supply chain constraints
- Regulatory pathway: Biosimilar guidance established but execution uncertain
---
Las dos caras hoy (sep-2026)
Alcista:
- Superciclo confirmado: $168B 2035, CAGR 22.4%, 890M eligible population
- Lilly lidera crecimiento: Tirzepatide $11.6B Q4 2025, Foundayo oral advantage, IRA protection until 2029
- Oral GLP-1s: Foundayo approved Apr 2026, Wegovy oral Dec 2025 → manufacturabilidad revolution
- Manufacturing $50B+ capex: API + fill-finish expansion, supply constraint through 2027
- Ecosystem value $1.2T: Healthcare system impact, food industry transformation
- Cartera Carlos 0% farma = hueco diversificación factorial real (innovación defensiva, healthcare secular)
Bajista:
- IRA pricing compression: Novo semaglutide exposed Jan 2027 → $274/month vs $959 list
- Manufacturing risk: Fill-finish capacity at risk if oral wins share faster than expected
- Persistence rates: Current 30-35% → needs >40% for sustainable system value
- Competition wave: Multiple entrants → pricing pressure, differentiation challenge
- Valoraciones: Multiples exigentes para líderes vs historia farmacéutica
---
Voces del cerebro y encaje con Carlos
- Posiciones: ninguna — hueco identificado cio-2026-07-16 (Inés Torres, estrategia sectorial).
- Candidatas cribadas tesis completa: eli-lilly (BUY, triple agonist, oral advantage, IRA protection).
- Nuevas watchlist entries: novo-nordisk (WATCHLIST, strong brand but IRA exposure), amgen (WATCHLIST, once monthly), boehringer ingelheim (WATCHLIST, NASH focus).
- Conceptos: foso-economico (manufacturing moat, API synthesis expertise) · ciclo de innovacion (oral vs injectable transformation) · valoracion-ciclicas-y-beneficios-negativos (no pagar de más por narrativa) · carteras-concentradas (diversificación factorial).
- Voces afines: philip-fisher (portfolio diversification) · howard-marks (innovation cycles, not linear extrapolation) · warren-buffett (moats en manufacturing y pipeline).
---
Análisis de segundo orden: Implicaciones sistémicas del superciclo GLP-1
El superciclo GLP-1 no es solo un boom farmacéutico — reescribe la economía del consumo, la sanidad y la cadena de valor industrial. Implicaciones de segundo orden:
1. Efecto rebote en sistema sanitario (2027-2030)
- Menor demanda cardiovascular → hospitales reducen procedimientos de stent/bypass → capacidad ociosa en cardiología → desplazamiento a otras especialidades.
- Coste diabetes complicaciones (amputaciones, diálisis, ceguera) ↓ 30-40% → liberación presupuestaria → presión pagadores para reinvertir en prevención, no solo tratamiento.
- Renal protection (GLP-1 + SGLT2) → retraso ESRD 5-7 años → impacto masivo en gasto Medicare/Medicaid (ESRD = 7% presupuesto Medicare).
2. Transformación cadena alimentaria (2026-2030)
- Hogares GLP-1: -12% snacks, -9% bebidas azucaradas, +7% proteína → rediseño portfolios food majors (Nestlé, Conagra, General Mills).
- Efecto red: Menos consumo calorías → menor demanda commodities (azúcar, maíz, soja para procesados) → precios agrícolas a la baja → impacto economías emergentes exportadoras.
- Nueva categoría: "GLP-1 companion foods" (alta proteína, porciones controladas) → premium pricing defensible → barrera entrada para food tech.
3. Geopolítica manufacturera (2027-2035)
- API synthesis expertise = nuevo foso económico (manufacturing moat) — Lilly $27B capex crea ventaja 5-7 años vs entrantes.
- Fill-finish bottleneck → outsourcing a CDMOs (Lonza, Catalent, Samsung Biologics) → concentración riesgo contraparte.
- Oral vs inyectable: Oral elimina cold chain → desbloqueo mercados emergentes (India, Brasil, África) donde logística fría es barrera.
4. IRA pricing como catalyst de acceso (2027+)
- Semaglutide $274/month vs $959 list (Jan 2027) → expansión cobertura Medicare Part D → 20M+ nuevos elegibles US.
- Tirzepatide protegido hasta 2029 → Lilly captura cuota mercado durante ventana protegida → refuerzo posición dominante.
- Efecto internacional: Precios US de referencia → presión precios EU/Japón → compresión márgenes global but volumen expansion.
5. Biosimilar cliff (2031-2033) — inflection point
- Semaglutide biosimilars 2033 → 70-80% price compression → democratización acceso masiva pero destrucción valor accionistas líderes.
- Estrategia Lilly: Triple agonist (retatrutide) + oral (orforglipron) → pipeline post-patent → transición valor a next-gen.
- Estrategia Novo: CagriSema + amylin oral (amycretin) → diferenciación clínica vs biosimilares semaglutide.
Falsable: Si biosimilares llegan 2030 (no 2033) → compresión anticipada → superciclo recortado 3-4 años.
---
Nota de evolución 2026-09-05 (elisa-fernandez)
Promoción desde scratchpad/industrias/salud-farma-glp1.md a wiki/industrias/salud-farma-glp1.md con fusión. Cambios vs versión wiki 2026-09-04:
- Análisis de segundo orden añadido (sección completa NUEVA): 5 implicaciones sistémicas — efecto rebote sanitario, transformación cadena alimentaria, geopolítica manufacturera, IRA pricing catalyst, biosimilar cliff 2031-2033.
- Menores ajustes terminológicos: "obesity" → "obesidad", "weight loss" → "pérdida de peso" en tablas para coherencia idioma.
- Fecha y agente actualizados para trazabilidad de promoción.
Falsable: IRA pricing compression >50% → superciclo overestimated; oral GLP-1s >50% share by 2030 → injectables obsolete; persistence rates <30% → system value overstated; biosimilars arrive 2030 (not 2033) → early compression cuts superciclo 3-4 years.
---
Ver también
— dato privado retirado —
---
Red de conexiones
- eli-lilly y novo-nordisk expresan lado duopolio GLP-1, donde pipeline y manufacturing importan más que narrativa individual.
- amgen y boehringer ingelheim expresan lado next wave, conectado con innovación en formulaciones y nuevas indicaciones.
- Materiales y energía enlazan industria con materias-primas-y-ciclo-de-commodities y energia limpia y transicion.
- Nuevo: glp1-superciclo = análisis técnico de mercado GLP-1 con fundamentales 2026-35.
- Nuevo: innovacion farmaceutica y biotech = panorama general innovación farmacéutica.